Supply of Birth Control Pills in the US at Risk as Tariffs Kick In
This article is for subscribers only.
Hi, it’s Satviki in Mumbai. President Donald Trump’s tariffs reached the health care sector last week. While levies are on patented drugs for now, the outsized reliance on Indian generics, especially in birth control pills, risks becoming a pain point for women in the US. More on that in a moment, but first ...
President Donald Trump’s call for 100% tariffs on branded and patented drug imports could raise prices for Americans, though many manufacturers could avoid the levies thanks to their investments in the US.